PEG & Drug Delivery Solutions

Complete PEG & Drug Delivery Solutions for Your Research

BOC Sciences offers a versatile portfolio of PEG-based delivery technologies tailored to the specific physicochemical properties of your payload. From improving the solubility of hydrophobic small molecules to extending the circulation half-life of complex biologics, our solutions cover the entire spectrum of drug delivery innovation.

Small Molecule PEGylation

• Design of PEG-drug conjugates (prodrugs) using ester, amide, or hydrazone linkers.
• Significant enhancement of aqueous solubility for hydrophobic compounds (Class II/IV).
• Reduction of metabolic degradation and prevention of rapid renal excretion.
• Custom synthesis of monodisperse PEG linkers for precise structure-activity relationship (SAR) studies.

Protein & Peptide PEGylation

• Site-specific conjugation (N-terminal, cysteine, or enzymatic tagging) to preserve bioactivity.
• Utilization of branched or multi-arm PEGs to create a stealth shield against proteolytic enzymes.
• Reduction of immunogenicity (anti-drug antibodies) and antigenicity in research models.
• Optimization of hydrodynamic volume to extend circulation half-life.

Liposomal & Nanocarrier Shielding

• Supply of high-purity PEG-lipids (DSPE-PEG, DMG-PEG) for lipid nanoparticle (LNP) formulation.
• Creation of stealth liposomes to evade uptake by the reticuloendothelial system (RES).
• Functionalization of PEG termini with ligands (folate, RGD, antibodies) for active targeting.
• Optimization of PEG molar ratios to control particle size and stability.

Antibody-Drug Conjugates (ADCs)

• Synthesis of hydrophilic PEG spacers to prevent aggregation of hydrophobic payloads.
• Design of cleavable vs. non-cleavable PEG linkers for controlled intracellular release.
• Improvement of the drug-to-antibody ratio (DAR) by masking hydrophobicity.
• Development of heterobifunctional PEG linkers for precise bioconjugation.

Oligonucleotide Delivery

• PEGylation of siRNA, antisense oligonucleotides (ASO), and aptamers.
• Protection against nuclease degradation in serum environments.
• Reduction of renal filtration rates to increase tissue accumulation.
• Conjugation with GalNAc-PEG derivatives for targeted liver delivery research.

PEG Hydrogel Depots

• Fabrication of cross-linked PEG hydrogels for sustained, local drug release.
• Tunable degradation kinetics (hydrolytic or enzymatic) for controlled release profiles.
• High loading capacity for proteins and small molecules without denaturation.
• Injectable systems for forming in-situ depots in preclinical models.

Efficient PEGylation & Formulation Services Tailored to You

Effective drug delivery is not just about attaching a polymer; it is about precise molecular engineering. BOC Sciences provides an end-to-end service workflow, from the synthesis of the activated PEG derivative to the final purification of the conjugate, ensuring that the biological activity of the drug is maintained while its delivery properties are optimized.

Molecular Design & Strategy

We begin by analyzing the structure and limitations of your API. Our experts propose a tailored PEGylation strategy, selecting the optimal PEG architecture (linear, branched, Y-shape), molecular weight (2kDa to 40kDa), and conjugation chemistry (N-hydroxysuccinimide, maleimide, click chemistry) to meet target pharmacokinetic profiles.

• Structure-activity relationship analysis.
• Selection of cleavable or stable linker systems.
• Simulation of hydrodynamic volume and shielding effects.

Custom PEG Synthesis

Success starts with high-quality raw materials. We synthesize high-purity, low-polydispersity PEG derivatives in-house. This allows us to create unique heterobifunctional PEGs or specific molecular weights that are not available in standard catalogs, ensuring your IP is unique and your product is reproducible.

• Synthesis of monodisperse PEGs for precise characterization.
• Manufacturing of multi-arm PEGs for high drug loading.
• Functionalization with reactive groups for specific conjugation sites.

Conjugation Process Development

Our team optimizes the reaction conditions (pH, stoichiometry, temperature, solvent) to maximize yield and specificity. For biologics, we focus on site-specific conjugation to prevent the masking of the active binding site, ensuring the drug retains its therapeutic potency.

• Optimization of PEG-to-protein molar ratios.
• Control of positional isomers in random conjugation.
• Scalable reaction processes from milligrams to kilograms.

Purification & Separation

Removing unreacted PEG, native drug, and by-products is critical for research integrity. We utilize advanced chromatography techniques to isolate the target mono-PEGylated or multi-PEGylated species with high purity, ensuring your downstream data is reliable.

• Size exclusion chromatography (SEC) and ion exchange (IEX).
• Removal of trace organic solvents and endotoxins.
• Ultrafiltration/Diafiltration (UF/DF) for buffer exchange.

Advanced Characterization Services for PEGylated Products

The polydispersity of PEG and the complexity of conjugates require specialized analytical techniques. BOC Sciences employs a comprehensive suite of analytical methods to verify the identity, purity, and dispersity of PEGylated drugs and PEGylated nanocarriers, providing data that meets stringent publication and regulatory research standards.

Why Partner with BOC Sciences?

• Expertise in Polymer Chemistry: Decades of experience in synthesizing complex PEG architectures (branched, star, dendritic) allows us to solve solubility issues that standard linear PEGs cannot.
• High-Quality Standards: We strictly control the PDI of our raw materials, ensuring that your final conjugates have consistent physicochemical properties batch-to-batch.
• Custom Synthesis Capabilities: Beyond catalog items, we design bespoke heterobifunctional linkers and drug-PEG conjugates tailored to your specific research hypothesis.
• Scalability: Our facilities support the seamless transition from milligram-scale R&D synthesis to kilogram-scale pilot production, supporting your project as it advances.
• Comprehensive Analysis: We don't just deliver a white powder; we provide a complete data package (COA) verifying structure, purity, and loading efficiency, reducing your validation burden.
• Problem-Solving Approach: Our formulation scientists work consultatively, offering strategies to overcome specific hurdles like aggregation, viscosity, or linker instability.
• Broad Application Range: Experience across all modalities—small molecules, peptides, proteins, antibodies, oligonucleotides, and nanoparticles.
• cGMP-Compliant Manufacturing: Our state-of-the-art cGMP facilities enable production under regulatory-compliant conditions, ensuring reproducible, high-quality PEG conjugates for preclinical use.

Project Workflow: From Concept to PEG Conjugates

We employ a systematic and transparent workflow to ensure project success. Whether you need a simple modification or a complex delivery system, our project management ensures timelines are met and quality is guaranteed.

Consultation & Feasibility

We begin by engaging with your scientific team to thoroughly evaluate the physicochemical properties of your API and your specific delivery objectives. Our experts analyze structural constraints to propose a technically feasible PEGylation strategy, selecting the optimal PEG architecture, molecular weight, and linker chemistry to precisely balance solubility enhancement with half-life extension.

Material Synthesis & Screening

We synthesize high-purity activated PEG derivatives in-house to ensure material quality. Concurrently, we conduct initial small-scale conjugation screening, rigorously testing various molar ratios, pH conditions, and reaction times. This screening phase allows us to rapidly identify the most promising reaction parameters that maximize conjugation efficiency while minimizing the formation of unwanted by-products.

Process Optimization

Once the lead candidate is selected, we systematically refine the conjugation process to maximize yield and product homogeneity. Our formulation scientists focus on developing robust purification strategies, utilizing advanced chromatography techniques to efficiently remove unreacted PEG, native drug, and isomers, ensuring the isolated conjugate meets the stringent purity standards required for downstream testing.

Scale-Up & Production

We seamlessly transition the optimized protocol from the laboratory bench to pilot-scale production to meet your material requirements. Our engineering team implements robust scale-up procedures, carefully controlling critical process parameters to ensure that batch-to-batch consistency, physicochemical properties, and impurity profiles remain stable and reproducible as production volumes increase from grams to kilograms.

QC & Characterization

The final PEGylated product undergoes a comprehensive suite of rigorous quality control tests to validate its structural identity and purity. We utilize advanced analytical methods, including NMR, HPLC, and MALDI-TOF MS, to generate a detailed COA. This documentation verifies molecular weight, polydispersity, and conjugation degree, ensuring full transparency.

Delivery & Support

We package and ship the final product under strictly controlled conditions to maintain stability during transit. Beyond delivery, our technical support team remains actively engaged to discuss analytical findings, interpret data, and provide expert guidance on handling, storage, or downstream formulation applications, ensuring seamless integration into your ongoing research pipeline.

Research Applications of PEG Delivery Systems

PEGylation is a ubiquitous technology in biomedical research. Our solutions enable breakthroughs across diverse therapeutic areas by improving the stability and delivery efficiency of experimental drugs.

Oncology Research

PEGylated nanocarriers and macromolecular conjugates exploit the enhanced permeability and retention (EPR) effect to accumulate passively in tumor tissues. PEG shielding reduces opsonization, allowing longer circulation times necessary for tumor uptake, while cleavable linkers allow for specific release within the tumor microenvironment.

Metabolic Disease Therapy

For peptide-based therapies (e.g., insulin, GLP-1 analogs) used in diabetes and obesity research, PEGylation significantly extends the plasma half-life. This allows researchers to study sustained therapeutic effects with reduced dosing frequency in animal models, mimicking long-acting formulations.

Gene Therapy & Vaccines

PEG-lipids are critical components of LNPs used to deliver mRNA and siRNA. The PEG layer prevents particle aggregation during storage and reduces immune clearance upon administration, ensuring the nucleic acid payload is successfully delivered to the target cells for expression or silencing.

Ophthalmology

PEGylation allows for the development of high-concentration anti-VEGF therapies and other intravitreal drugs. By increasing solubility and reducing viscosity, PEG enables smaller injection volumes and longer residence times in the vitreous humor, which is critical for developing treatments for retinal diseases.

Immunology & Inflammation

PEGylation of cytokines (e.g., Interferons, Interleukins) masks them from the immune system, reducing the formation of neutralizing antibodies. This maintains the efficacy of the biologic over time and reduces the risk of hypersensitivity reactions in preclinical safety studies.

Bio-imaging & Diagnostics

PEGylated iron oxide nanoparticles or quantum dots serve as stable contrast agents for MRI and fluorescence imaging. The PEG coating prevents non-specific binding to serum proteins, reducing background noise and improving the signal-to-noise ratio for precise imaging of tissues and organs.

Frequently Asked Questions

Have technical questions?

Contact Us

• What are the applications of PEG in drug delivery?

  Drug delivery technologies can enhance drug target delivery, minimize drug off-target effects and improve patient compliance. As therapeutics evolve from small molecules to nucleic acids, peptides, proteins, and antibodies, drug delivery technologies are also developing to address the new challenges. As a multifunctional conjugation ligand for drugs and drug delivery systems, PEG has been widely used as a solubilizing excipient in drug delivery system formulations. For example, PEGylation proteins can reduce the immunogenicity of proteins and prolong their half-life. PEGylated carbohydrates can be used as materials and carriers for new drugs. PEGylated oligonucleotides can improve solubility, nuclease resistance, and cell membrane permeability. PEGylated biomaterials can reduce thrombus formation and protein and cell adhesion.

• How does PEGylation improve drug solubility?

  PEG is a highly hydrophilic polymer. When conjugated to a hydrophobic small molecule or peptide, it effectively masks the hydrophobic regions and increases the hydration shell around the molecule. This significantly improves thermodynamic solubility in aqueous buffers, preventing precipitation and enabling higher concentration formulations.

• What is the difference between linear and branched PEG reagents?

  Linear PEGs provide a flexible, unencumbered chain, often used for simple half-life extension. Branched (e.g., Y-shape) or multi-arm PEGs create a dense "umbrella-like" shield. This increased steric bulk offers superior protection against proteolytic enzymes and antibodies, making branched PEGs ideal for highly immunogenic or unstable proteins.

• Can you synthesize PEG reagents with specific functional groups?

  Yes. We specialize in custom synthesis of heterobifunctional PEGs (e.g., Maleimide-PEG-NHS) and PEGs with bio-orthogonal groups (Azide, Alkyne, Tetrazine, DBCO). We can also control the molecular weight with high precision to meet your specific conjugation chemistry requirements.

• How do you control polydispersity (PDI) in your PEG products?

  We utilize advanced polymerization techniques and purification methods to minimize polydispersity. For applications requiring absolute precision, we offer discrete (monodisperse) PEGs where every molecule has the exact same chain length (PDI=1.0), eliminating mass spectrum complexity and regulatory ambiguity.

• Do you offer site-specific PEGylation services?

  Yes. Random PEGylation can lead to heterogeneous mixtures. We employ strategies such as N-terminal reductive alkylation, Cysteine-maleimide coupling, or enzymatic ligation to attach PEG to a specific residue. This ensures a homogeneous product profile and preserves the drug's receptor-binding affinity.

Case Studies and Success Stories

Publications

This section showcases the academic achievements of international research teams using BOC Sciences' products and services, highlighting our industry impact in lipid and PEG supply and development.

• Development and validation of rapid and simultaneous method for determination of 12 hair-growth compounds in adulterated products by UHPLC–MS/MS. Forensic science international 284 (2018): 129-135. PMID: 29408720 DOI: 10.1016/j.forsciint.2017.12.042.
• Hopanoids, like sterols, modulate dynamics, compaction, phase segregation and permeability of membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes (2019): 183060. DOI: 10.1016/j.bbamem.2019.183060.
• Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome. Pharmaceutics 14.9 (2022): 1895. PMID: 36145642 DOI: 10.3390/pharmaceutics14091895.
• Osteogenic effects of rapamycin on bone marrow mesenchymal stem cells via inducing autophagy. Journal of Orthopaedic Surgery and Research 18.1 (2023): 129. PMID: 36814286 DOI: 10.1186/s13018-023-03616-9.
• Liquid chromatography–tandem mass spectrometry method for the analysis of N-(3-aminopropyl)-N-dodecylpropane-1, 3-diamine, a biocidal disinfectant, in dairy products. Food chemistry 262 (2018): 168-177. DOI: 10.1016/j.foodchem.2018.04.080.

Client Testimonials

Industry Distribution of PEG & Drug Delivery Clients

"We struggled with the synthesis of a heterobifunctional PEG linker for our ADC project. BOC Sciences delivered the custom material with high purity and within a challenging timeline. The accompanying analytical data was thorough and reliable."

— Dr. James Anderson, Senior Scientist (USA)

"The team at BOC Sciences provided excellent guidance on selecting the right PEG architecture for our peptide. The resulting conjugate solved our stability issues without compromising bioactivity. A highly professional CDMO partner."

— Dr. Sophie Dubois, Biologics Lead (France)

"We required kilogram quantities of a high-quality mPEG-lipid for our nanoparticle formulation. BOC Sciences scaled up the production seamlessly, maintaining the strict specifications required for our preclinical studies."

— Mr. Hiroshi Tanaka, Formulation Manager (Japan)

"Their monodisperse PEG products are game-changers for analytical characterization. We can finally define our drug-linker ratio with precision. The technical support was also responsive and knowledgeable."

— Dr. Elena Rossi, Analytical Chemist (Italy)